Ulrich J, Gademann G, Gollnick H
Department of Dermatology and Venereology, Otto von Guericke University Medical School, Magdeburg, Germany.
J Neurooncol. 1999 Jun;43(2):173-8. doi: 10.1023/a:1006280304912.
We report results of a conservative treatment for brain metastases from malignant melanoma with a combination of irradiation and chemotherapy (fotemustine and/or DTIC). To date, 12 patients have been treated. There was a complete remission of the brain metastases in four patients. In two patients a partial remission was observed. The mean survival of the responder was 8.2 months (95% confidence interval 3.8-12.6 months). The most common side effects were thrombocytopenia, leukopenia, and alopecia. Altogether, the treatment was well tolerated. As the outcome of patients with brain metastases from malignant melanoma is generally poor, this combined chemo- and radiation therapy may provide improved care for such patients.
